Pre-clinical biotech company Telomir Pharmaceuticals has executed a binding letter of intent to acquire all worldwide rights to its lead investigational therapy, Telomir-1, by merging its U.S. rights with the ex-U.S. intellectual property held by TELI Pharmaceuticals. The company said that the combined portfolio spans markets including Europe, Canada, Mexico, China, Japan, South Korea, India, Israel, Australia, Argentina, Uruguay, Taiwan and the United Arab Emirates.
Under the terms of the transaction, each outstanding share of TELI common stock will be exchanged for Telomir shares based on an independent valuation. The deal also provides for up to US $5 million in shareholder contributions from certain TELI shareholders—US $1 million at closing, US $2 million upon IND acceptance, and US $2 million upon initiation of a Phase 1/2 trial—according to the company. The transaction remains subject to shareholder approval, regulatory and due diligence conditions.
Telomir said that the acquisition of worldwide rights converts Telomir-1 from a U.S.-focused asset into a global platform across oncology, metabolic and age-related diseases. The therapy is described as a small-molecule designed to reset DNA methylation, stabilise telomeres and restore gene regulation. Pre-clinical data cited by the company include activity in cancer cell-models, type 2 diabetes, agerelated macular degeneration and accelerated ageing syndromes.
The company noted that global oncology spending is projected to exceed US $400 billion by 2028, and that unified worldwide rights will enhance opportunities for partnerships, licensing or asset sales across regions. Telomir Pharmaceuticals claims the unified global structure will position it for significant long-term enterprise value creation.
